Trust issues with rivaroxaban (Xarelto) for atrial fibrillation?

References:
Elliot WJ. Circadian Variation in the Timing of Stroke Onset: A Meta-analysis. Stroke. 1998;29:992-996.

Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W.
Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin‐plasmin inhibitor complex. Circulation. 1997; 96: 19-21

Jung RG, Motazedian P, Ramirez FD, Simard T, Santo PD, Visintini S, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis. Thromb J. 2018;16:12.

Brunner-Ziegler, S, Jilma, B, Schörgenhofer, C, Winkler, F, Jilma-Stohlawetz, P, Koppensteiner, R, Quehenberger, P, Seger, C, Weigel, G, Griesmacher, A, Brunner, M. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects. J Thromb Haemost 2016; 14: 316–23.

Zhang L, Peters G, Haskell L, Patel P, Nandy P, Moore KT. A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies. J Clin Pharmacol. 2017 Dec;57(12):1607-1615. doi: 10.1002/jcph.958. Epub 2017 Jul 5. PMID: 28679020; PMCID: PMC5697651.

Scheer FA, Shea SA. Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle. Blood. 2014 Jan 23;123(4):590-3. doi: 10.1182/blood-2013-07-517060. Epub 2013 Nov 7. PMID: 24200683; PMCID: PMC3901072.

West, A.S.; Schønsted, M.I.; Iversen, H.K. Impact of the circadian clock on fibrinolysis and coagulation in healthy individuals and cardiovascular patients—A systematic review. Thromb. Res. 2021, 207, 75–84

Ray WA, Chung CP, Stein CM, et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA. 2021;326(23):2395–2404. doi:10.1001/jama.2021.21222